Phathom Pharmaceuticals (PHAT) vs Silence Therapeutics Plc American Depository Share (SLN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Silence Therapeutics Plc American Depository Share (SLN) has outperformed Phathom Pharmaceuticals (PHAT) over the past year, gaining 81.3% versus a loss of 35.5%. Over five years, SLN leads with a -56.4% price change compared with -78.1% for PHAT. Silence Therapeutics Plc American Depository Share is the larger company by market cap ($591.7 million vs $576.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PHAT | SLN |
|---|---|---|
| Share price | $7.13 | $9.52 |
| Market cap | $576.82M | $591.71M |
| 1-day change | +4.70% | -3.05% |
| YTD return | -57.02% | +56.58% |
| 1-year return | -35.48% | +81.33% |
| 5-year return | -78.07% | -56.37% |
| Forward P/E | 6.62 | — |
| EPS (TTM) | $-1.26 | $-1.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.31 | $17.58 |
| 52-week low | $6.52 | $4.19 |
| Distance from 52-week high | -61.06% | -45.84% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +186.82% | +246.64% |
| Average volume | 1.38M | 1.12M |
| Shares outstanding | 80.90M | 62.15M |
| Employees | 371 | 88 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLN has outperformed PHAT by 116.8 percentage points over the past year.
About Phathom Pharmaceuticals
PHAT stock →Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents.
Healthcare · Biotechnology · 371 employees
About Silence Therapeutics Plc American Depository Share
SLN stock →Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases.
Healthcare · Biotechnology · 88 employees
PHAT vs SLN FAQ
Which is bigger, Phathom Pharmaceuticals or Silence Therapeutics Plc American Depository Share?
Silence Therapeutics Plc American Depository Share (SLN) is larger, with a market capitalization of $591.71M compared with $576.82M for Phathom Pharmaceuticals (PHAT).
Which stock has performed better over the past year, PHAT or SLN?
SLN returned +81.33% over the past 12 months, compared with -35.48% for PHAT (price return, excluding dividends). Past performance does not predict future results.
Are Phathom Pharmaceuticals and Silence Therapeutics Plc American Depository Share in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.